Fibrinolysis Resistance in Infection and Trauma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAnders Aneman
About this trial
Blood coagulation disorders are often seen in critically ill patients e.g. with severe infection or following extensive injury, that can lead to life threatening events as a result of excessive blood clot formation leading to organ failure. This study aims to use Viscoelastic Testing (VET) technology to detect patients at risk of excessive blood blot formation at the bedside, test new blood coagulation drugs, and guide life-saving use of blood modifying treatments.
Eligibility criteria
Qualifiers
Admission to ICU, needing at least one organ supportand principally for the management of clinically suspected Sepsis or Septic shock according to Spesis-3 criteria (including SARS-COV-2)
Expected to remain in ICU and survive beyond the day after tomorrow
Disqualifiers
On oral anticoagulant/antiplatelet therapy
Not for full, active ICU support
Death is deemed inevitable within 24 hrs
Trauma is the principal diagnosis on ICU admission
Trial design
Treatments tested in this trial
- Viscoelastometric assessment of fibrinolysis
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Anders Aneman
Lead sponsor
South West Sydney Local Health District
Sponsor institution
Liverpool Hospital, South Western Sydney Local Health District
Collaborator
The Canberra Hospital
Collaborator
Royal North Shore Hospital
Collaborator
Macquarie University, Australia
Collaborator
Source ClinicalTrials.gov